Granules India: The financial results for the period ended September 30, 2026
Granules India (GRANULES) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹22,387 crore.
What happened
Granules India (GRANULES) filed a disclosure with the exchanges on 2 November 2026 at 04:48 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Granules India is a small-cap company in the Healthcare sector, with a market value of about ₹22,387 crore.
The stock last traded at ₹820.7, against a 52-week range of ₹529.9–₹923.7 (11.2% below the high).
Before this filing the shares had moved −3.1% over the month and +1.8% over three months. Average daily turnover over the last 20 sessions was about ₹56.19 crore.
Promoters held 37.39% at the end of Q2 FY27, down 0.63% points from the previous quarter. Foreign institutions owned 20.29% and domestic institutions 15.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,210 | 110.4 | 4.64 |
| Q2 FY26 | 1,297 | 130.6 | 5.38 |
| Q3 FY26 | 1,388 | 150.2 | 6.19 |
| Q4 FY26 | 1,471 | 201.6 | 8.23 |
| Q1 FY27 | 1,477 | 180 | 7.26 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.2% on average the next day and +1.8% over five days; 56% of them rose the next day.
Market-wide, 10,143 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 2 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Granules India USFDA inspection ends with 11 observations at Gagillapur
- Granules India Receives 11 USFDA Observations at Gagillapur Facility
- Granules India shares in focus after USFDA concludes Hyderabad facility inspection with 11 observations
- The Call Granules India Bulls Got Right
- Here's why Granules India shares could see a reaction on Monday
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.